Lipid Profile,Blood PressurePhase 1SBBU/IRC-25-31NCT07389304
[Effects of Selected Statins on Cardiovascular Parameters in Healthy Volunteers]
A Phase 1 study testing Rosuvastatin (5mg, 20mg, 40mg), Atorvastatin (10mg, 20mg, 40mg) and Simvastatin (10mg, 20mg, 40m in people with Lipid Profile,Blood Pressure, run by Shaheed Benazir Bhutto University Sheringal Dir Upper at 1 site in Pakistan.
Trial summary
This study is a Phase I randomized clinical trial aiming to investigate the short-term effects of three commonly prescribed statins i.e (Atorvastatin, Rosuvastatin, and Simvastatin) at different dose levels i.e lo,median and high doses on cardiovascular parameters i.e Blood pressure and ECG morphology in healthy… Read more about this study
- Who is it for?
- Ages 18 to 25 yearsHealthy volunteers can take part
- Conditions the study is for
- Lipid Profile,Blood Pressure
- What is being tested?
- Rosuvastatin (5mg, 20mg, 40mg), Atorvastatin (10mg, 20mg, 40mg) and Simvastatin (10mg, 20mg, 40m
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 sitePakistan
- Study dates
- 1 Mar 2026to 20 Feb 2027
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 25 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy volunteers
- Normal ECG
- Normal Blood Pressure
- Normal lipid levels
Who cannot join
- Participants with a history of diabetes mellitus,BP
- With chronic diseases e.g heart disease, kidney disease
- QTc ≥450 ms (men) or ≥470 ms (women)
- ECG changes
- Electrolyte imbalance,
- Participants taking other medications
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Pakistan1 site
Shaheed Benazir Bhutto University Sheringal Dir Upper
Dīr, Khyber Pakhtunkhwa
Dr.Abid Ullah, PhD, 0944885400, abid@sbbu.edu.pk
Professor Dr. Niaz Ali, PhD
About this study
Official title: [EFFECTS OF SELECTED STATINS ON CARDIOVASCULAR PARAMETERS IN HEALTHY VOLUNTEERS: A RANDAMOZIED PHASE I CLINICAL TRIAL]
This study is a Phase I randomized clinical trial aiming to investigate the short-term effects of three commonly prescribed statins i.e (Atorvastatin, Rosuvastatin, and Simvastatin) at different dose levels i.e lo,median and high doses on cardiovascular parameters i.e Blood pressure and ECG morphology in healthy volunteers. The study will assess changes in blood pressure and ECG morphology following two days of statin administration under controlled conditions.
Read the detailed description
The goal of this study is to evaluate the effects of these three statins on the cardiovascular parameters in a dose-dependent manner. In this Phase 1 clinical trial we will enroll healthy volunteers who will be randomized to receive one of three statins at low, moderate, or high doses for two days. .
- Conditions
- Lipid Profile,Blood Pressure
- Being tested
- Rosuvastatin (5mg, 20mg, 40mg), Atorvastatin (10mg, 20mg, 40mg), Simvastatin (10mg, 20mg, 40m
- Keywords
- sBlood Pressure,ECG change
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Rosuvastatin (5mg, 20mg, 40mg)Drug
The Rosuvastatin (5mg, 20mg, 40mg) group participants will be given the drug orally OD for two days
Atorvastatin (10mg, 20mg, 40mg)Drug
The Atorvastatin (10mg, 20mg, 40mg) group participants will be given the drug orally OD for two days
Simvastatin (10mg, 20mg, 40mDrug
The Simvastatin (10mg, 20mg, 40mg) group participants will be given the drug orally OD for two days
| Study group | Role | What they receive |
|---|---|---|
| Rosuvastatin (5mg, 20mg, 40mg) | Experimental | The assigned participants will be given Rosuvastatin 5mg, 20mg, 40mg OD for two days Receives: Drug: Rosuvastatin (5mg, 20mg, 40mg) |
| Atorvastatin (10mg,20mg, 40mg) | Experimental | The assigned participants will be given Atorvastatin 10mg,20mg, 40mg OD for two days Receives: Drug: Atorvastatin (10mg, 20mg, 40mg) |
| Simvastatin (10mg, 20mg, 40mg) | Experimental | The assigned participants will be given Simvastatin 10mg, 20mg, 40mg OD for two days Receives: Drug: Simvastatin (10mg, 20mg, 40m |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood Pressure Measurements
Blood Pressure of the subjects will be determined by sphygmomanometer
Measured: before dosing and 2 days after dosing achieving peak plasma concentrations respectively]
Secondary outcomes (1)
Electrocardiograms (ECGs) Measurements
ECGs of the subjects will be determined by 12 Leads ECG Machine.QT interval and QRS complex in milliseconds will be analyzed to determine the effects of these statins on ECG morphology
Measured: before dosing and 2 days after dosing achieving peak plasma concentrations respectively]
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Feb 2026
- Study start1 Mar 2026 (estimated)
- Primary completion30 Dec 2026 (estimated)
- Study completion20 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lipid Profile,Blood PressureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The selected statins i.e Simvastatin (5mg, 20mg, 40mg), atorvastatin (10mg,20mg, 40mg) and simvastatin(10mg, 20mg, 40mg) will be given orally to the participants of different assigned randomized participants groups in once daily dosing for two days to assess the effect on blood pressure and ECG.
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shaheed Benazir Bhutto University Sheringal Dir Upper
- Sponsor type
- University, hospital or other
- Collaborators
- Khyber Medical University Peshawar
- Responsible party
- Principal investigator, Dr Abid Ullah, Shaheed Benazir Bhutto University Sheringal Dir Upper
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07389304
- Sponsor's protocol ID
- [SBBU/PHM-25-32]
- Other IDs
- SBBU/IREC-25-32]
- Acronym
- SBBU/IRC-25-31
- Status last verified
- Jan 2026
- First submitted
- 20 Jan 2026
- Last updated
- 5 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The study results will be shared in well reputable Journals without the participant identifiers
Study at a glance
From the registry record, last updated by the sponsor on 5 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- [EFFECTS OF SELECTED STATINS ON CARDIOVASCULAR PARAMETERS IN HEALTHY VOLUNTEERS: A RANDAMOZIED PHASE I CLINICAL TRIAL]
- ClinicalTrials.gov ID
- NCT07389304
- Acronym / sponsor ID
- SBBU/IRC-25-31 / [SBBU/PHM-25-32]
- Conditions
- Lipid Profile,Blood Pressure
- Keywords
- sBlood Pressure,ECG change
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Shaheed Benazir Bhutto University Sheringal Dir UpperUniversity, hospital or other
- Collaborators
- Khyber Medical University Peshawar
- Study start
- 1 Mar 2026 (estimated)
- Primary completion
- 30 Dec 2026 (estimated)
- Study completion
- 20 Feb 2027 (estimated)
- First posted
- 5 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a Phase I randomized clinical trial aiming to investigate the short-term effects of three commonly prescribed statins i.e (Atorvastatin, Rosuvastatin, and Simvastatin) at different dose levels i.e lo,median and high doses on cardiovascular parameters i.e Blood pressure and ECG morphology in healthy volunteers. The study will assess changes in blood pressure and ECG morphology following two days of statin administration under controlled conditions.
Detailed description
The goal of this study is to evaluate the effects of these three statins on the cardiovascular parameters in a dose-dependent manner. In this Phase 1 clinical trial we will enroll healthy volunteers who will be randomized to receive one of three statins at low, moderate, or high doses for two days. .
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 3
- Model description
- The selected statins i.e Simvastatin (5mg, 20mg, 40mg), atorvastatin (10mg,20mg, 40mg) and simvastatin(10mg, 20mg, 40mg) will be given orally to the participants of different assigned randomized participants groups in once daily dosing for two days to assess the effect on blood pressure and ECG.
| Arm | Type | Receives |
|---|---|---|
| Rosuvastatin (5mg, 20mg, 40mg) | Experimental | Drug: Rosuvastatin (5mg, 20mg, 40mg)The assigned participants will be given Rosuvastatin 5mg, 20mg, 40mg OD for two days |
| Atorvastatin (10mg,20mg, 40mg) | Experimental | Drug: Atorvastatin (10mg, 20mg, 40mg)The assigned participants will be given Atorvastatin 10mg,20mg, 40mg OD for two days |
| Simvastatin (10mg, 20mg, 40mg) | Experimental | Drug: Simvastatin (10mg, 20mg, 40mThe assigned participants will be given Simvastatin 10mg, 20mg, 40mg OD for two days |
Who may qualify
- Ages
- 18 to 25 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Healthy volunteers
- Normal ECG
- Normal Blood Pressure
- Normal lipid levels
Key exclusion criteria (6 listed)
- Participants with a history of diabetes mellitus,BP
- With chronic diseases e.g heart disease, kidney disease
- QTc ≥450 ms (men) or ≥470 ms (women)
- ECG changes
- Electrolyte imbalance,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Rosuvastatin (5mg, 20mg, 40mg)The Rosuvastatin (5mg, 20mg, 40mg) group participants will be given the drug orally OD for two days | Drug | Rosuvastatin (5mg, 20mg, 40mg) |
| Atorvastatin (10mg, 20mg, 40mg)The Atorvastatin (10mg, 20mg, 40mg) group participants will be given the drug orally OD for two days | Drug | Atorvastatin (10mg,20mg, 40mg) |
| Simvastatin (10mg, 20mg, 40mThe Simvastatin (10mg, 20mg, 40mg) group participants will be given the drug orally OD for two days | Drug | Simvastatin (10mg, 20mg, 40mg) |
Primary outcome
Blood Pressure Measurements
Time frame: before dosing and 2 days after dosing achieving peak plasma concentrations respectively]
Blood Pressure of the subjects will be determined by sphygmomanometer
1 secondary outcome
Electrocardiograms (ECGs) Measurements
Time frame: before dosing and 2 days after dosing achieving peak plasma concentrations respectively]
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Feb 2026.
- Individual participant dataSharing planned: Yes. The study results will be shared in well reputable Journals without the participant identifiers
Related trials for Lipid Profile,Blood Pressure
Active, not recruitingObservational study
Expanded Studies on the SCAPIS Stockholm Reexamination Cohort
Coronary Artery Disease, Arterial Stiffness, Blood Pressure
Recruiting
How a Mediterranean Diet With Potatoes Impacts Heart and Metabolic Health in Adults With Pre-Diabetes
Prediabetes, Lipid Profile
Not yet recruiting
Impact of Date Consumption on Metabolic Control and Oxidative Stress in Patients With Type 2 Diabetes
Diabete Type 2
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Rosuvastatin (5mg, 20mg, 40mg), Atorvastatin (10mg, 20mg, 40mg) and Simvastatin (10mg, 20mg, 40m in people with Lipid Profile,Blood Pressure, run by Shaheed Benazir Bhutto University Sheringal Dir Upper at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Dr Abid Ullah, Ph.D (09448850 ext. 527, abid@sbbu.edu.pk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blood Pressure Measurements (time frame: before dosing and 2 days after dosing achieving peak plasma concentrations respectively]). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2026.